PALO ALTO, Calif., March 28, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter and year ended December 31, 2023.
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results
Kodiak Announces Presentation of First Time Results of KSI-501ABC Phase 1 Study
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023, at 3:25 p.m. Eastern Time (12:25 p.m. Pacific Time).
PALO ALTO, Calif., Nov. 6, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) today announced that its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe NPDR met its one-year primary endpoint.
Kodiak Sciences gave up on tarcocimab tedromer earlier this year after a pair of phase 3 trials ended in failure. But a fresh batch of late-stage data has now given the anti-VEGF drug another shot at approval.
PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco.
PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.
PALO ALTO, Calif., Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023, at 12:55 p.m. Eastern Time.